Physician profile
Mindy B Rennard
NPI 1851304240
$6,294.95
in general payments reported to CMS, 2019-2025
18 companies · $594 in 2025
The $594 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $334 · 2021: $899 · 2022: $994 · 2023: $1,384 · 2024: $974 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,205.85 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $1,114.80 | 2019-2025 | Precision 1, Hydrus Microstent, Total30 |
| Coopervision INC. | $805.62 | 2019-2025 | Misight Contact Lens, Cvi Contact Lens, Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $661.73 | 2019-2023 | Cequa |
| Allergan, INC. | $411.02 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $379.18 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $344.58 | 2019-2022 | |
| Biotissue Holdings INC. | $242.78 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $238.80 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $231.91 | 2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $173.57 | 2022-2025 | |
| Glaukos Corporation | $147.74 | 2021-2024 | Photrexa, Photrexa Cross-Linking Kit, Kxl System (Not Refurbished) |
| Abbvie INC. | $136.16 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $59.64 | 2021-2023 | |
| Oyster Point Pharma, INC. | $51.80 | 2022-2023 | Tyrvaya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Staar Surgical Company | $47.96 | 2019 | |
| Dompe US, INC. | $22.41 | 2025 | Oxervate |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Rennard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.